Abstract
To perform, from the Mexican NHS perspective, a cost-effectiveness analysis (CEA) of dupilumab in patients ≥6 years old as add-on therapy compared to Standard of Care (cyclosporine [CsA]+Best Supportive Care [BSC] OR BSC alone) for severe atopic dermatitis not adequately controlled under topical therapies or when those therapies are not recommended (base-case).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
